Concepts (229)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension | 13 | 2025 | 586 | 5.550 |
Why?
|
| Hypertension, Pregnancy-Induced | 4 | 2025 | 39 | 3.510 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 4 | 2025 | 38 | 3.380 |
Why?
|
| Cardiovascular Diseases | 8 | 2025 | 835 | 1.660 |
Why?
|
| Blood Pressure | 10 | 2025 | 512 | 1.650 |
Why?
|
| Cardiomyopathies | 3 | 2024 | 125 | 1.580 |
Why?
|
| Natriuretic Peptide, Brain | 5 | 2025 | 55 | 1.360 |
Why?
|
| Antihypertensive Agents | 4 | 2021 | 167 | 1.340 |
Why?
|
| Dietary Approaches To Stop Hypertension | 4 | 2023 | 9 | 1.310 |
Why?
|
| Pregnancy Complications, Cardiovascular | 3 | 2025 | 36 | 1.290 |
Why?
|
| Pregnancy | 13 | 2025 | 2334 | 1.180 |
Why?
|
| Troponin I | 3 | 2025 | 35 | 1.170 |
Why?
|
| Peptide Fragments | 4 | 2025 | 410 | 1.160 |
Why?
|
| Pre-Eclampsia | 3 | 2024 | 71 | 1.070 |
Why?
|
| Myocardial Ischemia | 2 | 2025 | 117 | 1.060 |
Why?
|
| Cardiac Rehabilitation | 2 | 2025 | 67 | 1.040 |
Why?
|
| Heart Failure | 5 | 2025 | 913 | 0.960 |
Why?
|
| Telemedicine | 3 | 2025 | 326 | 0.960 |
Why?
|
| Nutrition Surveys | 5 | 2022 | 142 | 0.930 |
Why?
|
| Narration | 1 | 2025 | 51 | 0.900 |
Why?
|
| Contraception | 2 | 2022 | 71 | 0.880 |
Why?
|
| Ventricular Premature Complexes | 1 | 2024 | 21 | 0.870 |
Why?
|
| Echocardiography | 5 | 2024 | 501 | 0.850 |
Why?
|
| Female | 36 | 2025 | 32880 | 0.850 |
Why?
|
| Adult | 25 | 2025 | 16824 | 0.840 |
Why?
|
| Humans | 48 | 2025 | 63445 | 0.810 |
Why?
|
| Mobile Applications | 1 | 2025 | 136 | 0.790 |
Why?
|
| Contraceptive Effectiveness | 1 | 2022 | 3 | 0.760 |
Why?
|
| Patient Compliance | 1 | 2024 | 360 | 0.760 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2023 | 165 | 0.760 |
Why?
|
| Contraceptive Agents | 1 | 2022 | 12 | 0.750 |
Why?
|
| Tachycardia, Ventricular | 1 | 2024 | 129 | 0.750 |
Why?
|
| Young Adult | 10 | 2025 | 4694 | 0.750 |
Why?
|
| Polycystic Ovary Syndrome | 1 | 2021 | 23 | 0.710 |
Why?
|
| Health Promotion | 1 | 2025 | 497 | 0.690 |
Why?
|
| Social Determinants of Health | 1 | 2023 | 132 | 0.670 |
Why?
|
| Qualitative Research | 1 | 2024 | 690 | 0.650 |
Why?
|
| Cardiology | 1 | 2022 | 168 | 0.650 |
Why?
|
| Obesity, Abdominal | 1 | 2019 | 9 | 0.630 |
Why?
|
| C-Reactive Protein | 4 | 2025 | 166 | 0.590 |
Why?
|
| Inflammation Mediators | 1 | 2019 | 177 | 0.570 |
Why?
|
| Risk Factors | 9 | 2025 | 5354 | 0.550 |
Why?
|
| Point-of-Care Systems | 1 | 2018 | 131 | 0.510 |
Why?
|
| United States | 12 | 2025 | 7843 | 0.510 |
Why?
|
| Cross-Sectional Studies | 7 | 2025 | 2576 | 0.450 |
Why?
|
| Health Surveys | 1 | 2015 | 313 | 0.430 |
Why?
|
| Biomarkers | 7 | 2025 | 1408 | 0.410 |
Why?
|
| Middle Aged | 17 | 2025 | 17613 | 0.410 |
Why?
|
| Stroke Volume | 3 | 2023 | 329 | 0.370 |
Why?
|
| Practice Guidelines as Topic | 1 | 2015 | 724 | 0.360 |
Why?
|
| Sinusitis | 1 | 2011 | 31 | 0.350 |
Why?
|
| Vital Capacity | 1 | 2011 | 118 | 0.350 |
Why?
|
| Forced Expiratory Volume | 1 | 2011 | 209 | 0.340 |
Why?
|
| Endoscopy | 1 | 2011 | 110 | 0.330 |
Why?
|
| Cystic Fibrosis | 1 | 2011 | 121 | 0.330 |
Why?
|
| Ventricular Remodeling | 2 | 2021 | 83 | 0.320 |
Why?
|
| Gout | 3 | 2015 | 48 | 0.310 |
Why?
|
| Socioeconomic Factors | 1 | 2011 | 777 | 0.300 |
Why?
|
| Heart | 3 | 2019 | 283 | 0.290 |
Why?
|
| Aged | 10 | 2025 | 14447 | 0.280 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2025 | 153 | 0.260 |
Why?
|
| Furosemide | 2 | 2018 | 20 | 0.260 |
Why?
|
| Sodium | 2 | 2023 | 61 | 0.260 |
Why?
|
| Diuretics | 2 | 2018 | 59 | 0.260 |
Why?
|
| Male | 17 | 2025 | 29891 | 0.250 |
Why?
|
| Pregnancy Outcome | 2 | 2025 | 194 | 0.240 |
Why?
|
| Ebstein Anomaly | 1 | 2025 | 5 | 0.240 |
Why?
|
| High-Intensity Interval Training | 1 | 2025 | 2 | 0.230 |
Why?
|
| HMGB1 Protein | 1 | 2025 | 25 | 0.230 |
Why?
|
| Glucose | 2 | 2023 | 467 | 0.230 |
Why?
|
| Peripartum Period | 1 | 2024 | 21 | 0.220 |
Why?
|
| Heart Diseases | 2 | 2024 | 218 | 0.220 |
Why?
|
| Smartphone | 1 | 2025 | 69 | 0.210 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2024 | 100 | 0.210 |
Why?
|
| Troponin T | 2 | 2023 | 24 | 0.200 |
Why?
|
| Dyspnea | 1 | 2024 | 124 | 0.200 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2025 | 216 | 0.200 |
Why?
|
| Focus Groups | 1 | 2024 | 303 | 0.200 |
Why?
|
| Echocardiography, Three-Dimensional | 1 | 2023 | 44 | 0.200 |
Why?
|
| Heart Ventricles | 2 | 2023 | 261 | 0.200 |
Why?
|
| Electrocardiography | 2 | 2024 | 554 | 0.190 |
Why?
|
| Sterilization, Reproductive | 1 | 2022 | 8 | 0.190 |
Why?
|
| Catheter Ablation | 1 | 2024 | 153 | 0.190 |
Why?
|
| Case-Control Studies | 1 | 2025 | 1119 | 0.190 |
Why?
|
| Health Behavior | 1 | 2025 | 469 | 0.180 |
Why?
|
| Insulin Resistance | 1 | 2025 | 412 | 0.180 |
Why?
|
| Diet, Sodium-Restricted | 1 | 2021 | 5 | 0.180 |
Why?
|
| Health Status Disparities | 1 | 2023 | 146 | 0.180 |
Why?
|
| Early Detection of Cancer | 1 | 2024 | 322 | 0.180 |
Why?
|
| Atherosclerosis | 1 | 2022 | 153 | 0.180 |
Why?
|
| Vital Signs | 1 | 2021 | 12 | 0.170 |
Why?
|
| Fellowships and Scholarships | 1 | 2022 | 108 | 0.170 |
Why?
|
| Needs Assessment | 1 | 2022 | 199 | 0.170 |
Why?
|
| Diet, Fat-Restricted | 1 | 2020 | 33 | 0.160 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2025 | 761 | 0.160 |
Why?
|
| Asthma | 1 | 2024 | 459 | 0.160 |
Why?
|
| Prospective Studies | 2 | 2025 | 3293 | 0.160 |
Why?
|
| Dietary Fats, Unsaturated | 1 | 2019 | 20 | 0.160 |
Why?
|
| Retrospective Studies | 7 | 2025 | 6658 | 0.160 |
Why?
|
| Stress, Psychological | 1 | 2024 | 470 | 0.160 |
Why?
|
| Dietary Proteins | 1 | 2019 | 42 | 0.150 |
Why?
|
| Dietary Carbohydrates | 1 | 2019 | 61 | 0.150 |
Why?
|
| Infant, Newborn | 3 | 2025 | 1358 | 0.150 |
Why?
|
| Cross-Over Studies | 1 | 2019 | 161 | 0.150 |
Why?
|
| Ventricular Function, Left | 1 | 2021 | 268 | 0.150 |
Why?
|
| Aortic Valve | 1 | 2021 | 190 | 0.150 |
Why?
|
| Transcatheter Aortic Valve Replacement | 1 | 2021 | 110 | 0.150 |
Why?
|
| Lung Neoplasms | 1 | 2024 | 674 | 0.140 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2024 | 698 | 0.140 |
Why?
|
| Aortic Valve Stenosis | 1 | 2021 | 189 | 0.140 |
Why?
|
| Curriculum | 1 | 2022 | 599 | 0.140 |
Why?
|
| Dopamine | 1 | 2018 | 106 | 0.140 |
Why?
|
| Uric Acid | 2 | 2015 | 47 | 0.140 |
Why?
|
| Triage | 1 | 2018 | 126 | 0.130 |
Why?
|
| Atrial Appendage | 1 | 2017 | 33 | 0.130 |
Why?
|
| Coronary Circulation | 1 | 2017 | 52 | 0.130 |
Why?
|
| Sleep | 1 | 2019 | 225 | 0.130 |
Why?
|
| Sarcoidosis | 1 | 2017 | 33 | 0.130 |
Why?
|
| Myocarditis | 1 | 2017 | 67 | 0.120 |
Why?
|
| Infant | 3 | 2023 | 1645 | 0.120 |
Why?
|
| Cardiac Catheterization | 1 | 2017 | 283 | 0.120 |
Why?
|
| Gout Suppressants | 1 | 2015 | 22 | 0.120 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2015 | 39 | 0.110 |
Why?
|
| Forecasting | 1 | 2015 | 232 | 0.110 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2017 | 266 | 0.100 |
Why?
|
| Hyperuricemia | 1 | 2013 | 7 | 0.100 |
Why?
|
| Receptors, Opioid | 1 | 2012 | 16 | 0.100 |
Why?
|
| Clonidine | 1 | 2012 | 25 | 0.100 |
Why?
|
| Oxycodone | 1 | 2012 | 30 | 0.090 |
Why?
|
| Narcotics | 1 | 2012 | 58 | 0.090 |
Why?
|
| Treatment Outcome | 4 | 2021 | 5680 | 0.090 |
Why?
|
| Analgesics | 1 | 2012 | 102 | 0.090 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2012 | 49 | 0.090 |
Why?
|
| Obesity | 1 | 2019 | 1235 | 0.090 |
Why?
|
| Comorbidity | 2 | 2013 | 1120 | 0.090 |
Why?
|
| Kidney Diseases | 1 | 2013 | 176 | 0.090 |
Why?
|
| Risk Assessment | 1 | 2018 | 2079 | 0.090 |
Why?
|
| Disease Progression | 1 | 2015 | 1172 | 0.090 |
Why?
|
| Respiratory Insufficiency | 1 | 2012 | 155 | 0.080 |
Why?
|
| Prevalence | 3 | 2024 | 1380 | 0.080 |
Why?
|
| Diet | 2 | 2023 | 527 | 0.080 |
Why?
|
| Atrial Fibrillation | 1 | 2017 | 834 | 0.070 |
Why?
|
| Cytokines | 1 | 2012 | 935 | 0.070 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2008 | 45 | 0.070 |
Why?
|
| Stroke | 1 | 2017 | 1196 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2008 | 108 | 0.070 |
Why?
|
| Adolescent | 2 | 2025 | 6245 | 0.070 |
Why?
|
| Longitudinal Studies | 1 | 2011 | 1256 | 0.070 |
Why?
|
| Analgesics, Opioid | 1 | 2012 | 536 | 0.070 |
Why?
|
| Glioblastoma | 1 | 2008 | 157 | 0.060 |
Why?
|
| NF-kappa B | 1 | 2008 | 469 | 0.060 |
Why?
|
| Aged, 80 and over | 3 | 2025 | 5462 | 0.060 |
Why?
|
| Child, Preschool | 1 | 2011 | 1990 | 0.060 |
Why?
|
| Cohort Studies | 1 | 2011 | 2570 | 0.060 |
Why?
|
| Peptide Nucleic Acids | 1 | 2004 | 16 | 0.060 |
Why?
|
| Nucleic Acid Heteroduplexes | 1 | 2004 | 15 | 0.060 |
Why?
|
| Physical Conditioning, Animal | 1 | 2025 | 43 | 0.060 |
Why?
|
| Pericardial Effusion | 1 | 2024 | 21 | 0.050 |
Why?
|
| Home Care Services | 1 | 2025 | 98 | 0.050 |
Why?
|
| Surface-Active Agents | 1 | 2004 | 113 | 0.050 |
Why?
|
| Pericardium | 1 | 2023 | 35 | 0.050 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2025 | 131 | 0.050 |
Why?
|
| Hospitalization | 2 | 2025 | 1364 | 0.050 |
Why?
|
| Apoptosis | 1 | 2008 | 1079 | 0.050 |
Why?
|
| Heart Defects, Congenital | 1 | 2024 | 103 | 0.050 |
Why?
|
| Heart Valve Diseases | 1 | 2024 | 95 | 0.050 |
Why?
|
| Heart Atria | 1 | 2023 | 137 | 0.050 |
Why?
|
| Glomerular Filtration Rate | 2 | 2013 | 112 | 0.050 |
Why?
|
| Vegetables | 1 | 2022 | 69 | 0.050 |
Why?
|
| Child | 1 | 2011 | 4526 | 0.040 |
Why?
|
| Systole | 1 | 2021 | 108 | 0.040 |
Why?
|
| Protein Precursors | 1 | 2020 | 83 | 0.040 |
Why?
|
| Smoking | 1 | 2024 | 866 | 0.040 |
Why?
|
| Heart Valve Prosthesis | 1 | 2021 | 113 | 0.040 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 2018 | 11 | 0.040 |
Why?
|
| Injections, Intravenous | 1 | 2018 | 156 | 0.040 |
Why?
|
| Creatinine | 1 | 2018 | 134 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2018 | 173 | 0.040 |
Why?
|
| Contraindications, Drug | 1 | 2017 | 1 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2025 | 3396 | 0.030 |
Why?
|
| Nitrogen Radioisotopes | 1 | 2017 | 16 | 0.030 |
Why?
|
| Hyperemia | 1 | 2017 | 13 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2018 | 465 | 0.030 |
Why?
|
| Ammonia | 1 | 2017 | 14 | 0.030 |
Why?
|
| Blood Flow Velocity | 1 | 2017 | 72 | 0.030 |
Why?
|
| Vasodilation | 1 | 2017 | 36 | 0.030 |
Why?
|
| Acute Disease | 1 | 2018 | 671 | 0.030 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2017 | 98 | 0.030 |
Why?
|
| Prosthesis Design | 1 | 2017 | 229 | 0.030 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2017 | 52 | 0.030 |
Why?
|
| Myocardial Perfusion Imaging | 1 | 2017 | 51 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2017 | 165 | 0.030 |
Why?
|
| Inflammation | 1 | 2023 | 1147 | 0.030 |
Why?
|
| Radiopharmaceuticals | 1 | 2017 | 189 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2021 | 2458 | 0.030 |
Why?
|
| Mice | 2 | 2025 | 10844 | 0.030 |
Why?
|
| Therapeutics | 1 | 2015 | 5 | 0.030 |
Why?
|
| Patient Selection | 1 | 2017 | 490 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2017 | 378 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2017 | 1094 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2015 | 162 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2015 | 311 | 0.030 |
Why?
|
| Anticoagulants | 1 | 2017 | 495 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2015 | 937 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2013 | 864 | 0.020 |
Why?
|
| Animals | 2 | 2025 | 20663 | 0.020 |
Why?
|
| Infant, Premature | 1 | 2012 | 184 | 0.020 |
Why?
|
| Quality Improvement | 1 | 2015 | 443 | 0.020 |
Why?
|
| Drug Overdose | 1 | 2012 | 131 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2017 | 1644 | 0.020 |
Why?
|
| Gene Expression | 1 | 2012 | 840 | 0.020 |
Why?
|
| Time Factors | 1 | 2017 | 3768 | 0.020 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2008 | 12 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2008 | 109 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2008 | 277 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2008 | 190 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2008 | 456 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2008 | 454 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2008 | 519 | 0.020 |
Why?
|
| Caspases | 1 | 2008 | 174 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2008 | 612 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2008 | 936 | 0.020 |
Why?
|
| Mitochondria | 1 | 2008 | 371 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2008 | 629 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2008 | 988 | 0.010 |
Why?
|
| RNA, Small Interfering | 1 | 2008 | 921 | 0.010 |
Why?
|
| Protein Binding | 1 | 2004 | 1603 | 0.010 |
Why?
|
| DNA | 1 | 2004 | 837 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2008 | 3035 | 0.010 |
Why?
|